Hansoh Pharma Announces HK$3.92 Billion Placement to Accelerate Innovative Drug Development as Innovative Portfolio Revenue Rises to 82.7%

　　【Pharmaceutical Network Medical Stock Market】Recently, Hansoh Pharma, a Hong Kong-listed biopharmaceutical company, announced a plan to place 108 million new shares at a price of HK$36.30 per share. This placement is expected to raise approximately HK$3.92 billion in total proceeds. After deducting related expenses, the net proceeds will amount to about HK$3.897 billion. According to the announcement, these funds will primarily be used for R&D investment in the company’s core pharmaceutical products, expansion and upgrading of production facilities, as well as the development of sales channels in both domestic and international markets.
 

From the perspective of this placement plan, Hansoh Pharma's pricing strategy and the use of funds raised both reflect a distinct strategic orientation. The placement price of HK$36.30 per share represents a discount of approximately 5% compared to the average closing price over the five trading days prior to the announcement, falling within the common discount range for placements in the Hong Kong stock market. This approach not only protects the interests of existing shareholders from excessive dilution but also provides institutional investors participating in the placement with a certain margin of safety. The company's board stated that this financing initiative will support the group’s business development, broaden the shareholder base, and emphasized that the placement terms are fair and reasonable, aligning with the overall interests of the company and its shareholders. In terms of market reaction, on the first trading day after the announcement, Hansoh Pharma’s share price fell only slightly by 1.2%, without significant fluctuations, indicating market approval of the placement plan.
 

As can be seen from the company announcement, the use of proceeds from this placement by Hansoh Pharma is clearly planned: approximately 65% will be invested in the research and development of new innovative drugs in therapeutic areas such as oncology, autoimmune diseases, central nervous system, and metabolic disorders, as well as licensing of innovative drugs and innovative technology platforms; around 25% will be used for the construction of new production facilities and R&D laboratories for innovative drugs, and upgrading the group’s existing R&D laboratories and production facilities; and about 10% will be allocated for working capital and other general corporate purposes.
 

It is reported that Hansoh Pharma, as an enterprise in the field of innovative drugs in China, has been continuously making efforts in core therapeutic areas such as oncology, autoimmune diseases, and central nervous system diseases in recent years. The net proceeds of 3.897 billion Hong Kong dollars from this offering will further enrich its R&D pipeline.
 

Data shows that the average R&D cycle for an innovative drug from preclinical research to market launch takes 8-10 years, with an average investment exceeding 1 billion US dollars. Industry insiders indicate that biopharmaceutical companies listed on the Hong Kong Stock Exchange generally rely on external financing to support R&D investments. This has become a significant reason for Hansoh Pharma to choose this current timing for placement. Additionally, the capital investment in production base expansion and sales channel development can not only address the capacity bottleneck after the launch of innovative drugs but also accelerate the commercialization process of products in domestic and international markets, forming a closed-loop growth of "R&D - Production - Sales."
 

Hansoh Pharma's top-up placement is not an isolated event. Looking back at the dynamics of the Hong Kong stock market in the past three years, top-up placements in the biopharmaceutical sector have been commonplace. In 2023, Wuxi Biologics carried out a placement of 220 million shares at HK$72 per share, raising approximately HK$15.84 billion for the construction of biopharmaceutical production bases and the layout of global R&D centers. At the beginning of 2024, CSPC Pharmaceutical Group also launched a placement plan of 150 million shares at HK$11.8 per share, raising HK$1.77 billion, mainly for investment in clinical research of innovative drugs. These cases all exhibit the characteristics of "high pricing, institution-led, and R&D-focused," forming a unique financing ecosystem in the Hong Kong stock market's biopharmaceutical sector.
 

In addition, just one day before Hansoh Pharma announced its placement, Ascletis Pharma also issued an announcement stating that it would conduct a share placement in a "sell old, buy new" manner at a placement price of HK$16.45 per share, representing a discount of approximately 9.9% compared to the closing price of the previous day. In this placement, Wu Jinzi, the controlling shareholder and founder of the company, sold 52.4 million shares at HK$16.45 per share while subscribing to 28.82 million new shares, cashing out approximately HK$388 million. Following the completion of the placement and subscription, the controlling shareholder’s stake will decrease from 62.21% to 58.03%.
 

Why the Hong Kong stock market has become a "fertile ground" for high-level placements by biopharmaceutical companies is mainly due to the dual drivers of market structure and industry attributes. In terms of market structure, institutional investors dominate the Hong Kong stock market, accounting for over 60%. These institutional investors have a higher recognition of the long-term value of biopharmaceutical companies and are more willing to participate in placements during the high-growth phase of a company to share in its growth dividends. Meanwhile, the placement system in the Hong Kong stock market is relatively flexible, allowing companies to quickly initiate financing based on their capital needs without going through complex approval processes, providing convenience for urgent R&D investments by biopharmaceutical companies.
 

Hansoh Pharma's HKD 3.9 Billion High-Position Placement: A Strategic Choice for Corporate Development and a Microcosm of the Financing Ecosystem in Hong Kong's Biomedical Sector
 

It was reported that Hansoh Pharma recently released its 2025 half-year financial report. The report shows that in the first half of the year, Hansoh Pharma achieved an income of approximately RMB 7.434 billion, representing a year-on-year increase of about 14.3%; net profit reached approximately RMB 3.135 billion, marking a year-on-year growth of about 15.0%. In the first half of the year, the revenue from innovative drugs and collaborative products amounted to RMB 6.145 billion, increasing by 22.1% year-on-year, accounting for 82.7% of total revenue. The revenue from innovative drugs and collaborative products became the main driver of performance growth during the reporting period.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.